Completed PHASE2 INTERVENTIONAL 4-arm NCT00279825

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Compare IPX054 200 mg and 250 mg to CD-LD IR 200 (2x100) mg Tablets and CD-LD CR 200 mg Tablet in Subjects With Parkinson's Disease

Sponsor: Impax Laboratories, LLC

Conditions Idiopathic Parkinson's Disease

Interventions CD-LD CR CD-LD CR Placebo CD-LD IR CD-LD IR Placebo IPX054 200 mg IPX054 200 mg Placebo IPX054 250 mg IPX054 250 mg Placebo

Updated 8 times since 2017 Last updated: Oct 25, 2019 Started: Jan 31, 2006 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Idiopathic Parkinson's Disease and is currently completed. Impax Laboratories, LLC leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2
Jul 2019 — Nov 2019 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jul 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Impax Laboratories, LLC

Data source: Impax Laboratories, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bingham Farms, United States
• Portland, United States